Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.48 |
| ▸ | ITGAV | P06756 | 19/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 15/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 15/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499724 | 0.88 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6487610 | 0.84 | MAPT (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6646068 | 0.82 | ITGB3 (0.41) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6809884 | 0.82 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6800425 | 0.81 | ITGB3 (0.43) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6787323 | 0.80 | POLB (0.42) | ITGB3ITGAVITGB1ITGA5CHRNB2 | |
| SCHEMBL6502934 | 0.79 | MTTP (0.40) | ITGB3ITGAVITGB1ITGA5CHRNB2 | |
| SCHEMBL6489654 | 0.79 | APOB (0.40) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6490619 | 0.79 | ITGB3 (0.39) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6650060 | 0.79 | ITGB3 (0.40) | ITGB3ITGAVITGB1ITGA5CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | ITGB3 2131/4885ITGAV 3611/4885ITGB6 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.